Marubi(SH:603983) Ge Long Hui·2025-11-12 10:47Core Viewpoint - Mamei Biotechnology (603983.SH) plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its capital strength and overseas financing capabilities, aiming to accelerate its international business strategy [1] Group 1: Company Strategy - The company intends to strengthen its overall competitiveness and accelerate its internationalization strategy through the issuance of H-shares [1] - The decision aligns with the company's overall development strategy and operational needs [1] Group 2: Shareholder Considerations - The company will consider the interests of existing shareholders and the conditions of domestic and international capital markets when proceeding with the issuance [1] - The issuance and listing will be completed at an appropriate time within 24 months from the shareholders' meeting resolution, with the possibility of extension [1] Group 3: Regulatory and Market Conditions - The specific timing for the issuance and listing will be determined by the board of directors based on international capital market conditions and the progress of regulatory approvals [1] - The company has disclosed relevant announcements on the Shanghai Stock Exchange regarding this plan [1]